Innate will receive $5M up front, ~$410M upon achievement of development, regulatory & commercial milestones along with royalties on net sales of any commercial product
Takeda gets an exclusive right globally to research & develop ADC using a panel of selected Innate Abs against an undisclosed target with an initial focus on Celiac disease. Takeda will lead the future development, manufacture & commercialization of any potential products developed using licensed Abs
The lead proprietary program lacutamab, developed for advanced cutaneous & peripheral T cell lymphomas, monalizumab, an NSCLC treatment co-developed with AstraZeneca & ANKET multi-specific NK cell engagers for multiple tumor types are all included in Innate’s portfolio
Ref: Businesswire | Image: Innate
Related News:- Sanofi Expands its 2016 Agreement with Innate Pharma for Natural Killer Cell Therapies in Oncology
